The Newborn Screening (NBS) Market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% from 2023 to 2030. Newborn screening tests are performed for the early identification of the conditions that can affect the child’s survival or long-term health. The screening technology specifies a series of essential tests for early detection, health management, timely diagnosis, management, and prevention of disabilities in newborns. These tests are performed in a short period of time after the child is born to detect metabolic, genetic, and developmental disorders in children. The screening is usually done by collecting blood samples from newborns’ heels for different endocrine, metabolic, and genetic disorders. The newborns are also tested for critical congenital heart disease (CCHD) and hearing defects before the child is discharged from the birthing center or hospital. Some of the tests carried out to detect these anomalies include OAE screening and PKU tests.
The rising prevalence of congenital heart diseases and genetic disorders, the increasing neonatal population, and the rising awareness regarding newborn screening are the factors driving the growth of the newborn screening market. Additionally, emerging economies and government programs & legislation promoting newborn screening serve as opportunities for the market.
However, the shortage of healthcare professionals and the emergence of non-invasive prenatal screening technologies restrain the market’s growth. Additionally, ethical concerns related to newborn screening and the high costs of genomic newborn screening tests are some of the challenging factors in the market.
Ever since its introduction in the early 1960s, newborn screening tests have been carried out using traditional technologies such as tandem mass spectrometry and biochemical testing, among others. These technologies are effective and reliable; however, the emergence of advanced technologies has improved the accuracy of results. Next-generation sequencing (NGS) and artificial intelligence (AI) are two of the most researched technologies in the newborn screening industry.
These technologies are still in the research phase but are being tested to screen newborns. NGS screening will help screen more disorders compared to other conventional technologies using techniques such as targeted gene panels, whole exome sequencing (WES), and whole genome sequencing (WGS). NGS technology will also follow the Wilson and Jungner principles to identify genes associated with treatable disorders. It is economically feasible, and many tools and software are available for interpreting results.
Another technology that can be incorporated along with conventional methods is artificial intelligence. A study was conducted at the Neonatal Disease Screening Center of the Maternal and Child Health Hospital in Shaoyang City (China) to screen newborns for inborn errors of metabolism. In total, 96,648 newborns were enrolled during 2016-2020. An AI algorithm was used to analyze the screening results. According to the results, 1,988 newborns were screened, and 23 of them were confirmed to have an inborn error of metabolism. It was also observed that the occurrence of false positives could be decreased by more than 24.9%, improving screening efficiency.
Increasing Neonatal Population
Newborn screening has been recognized and initiated by governments of various countries worldwide due to the high prevalence of genetic and/or metabolic conditions in newborns. Owing to the increasing importance of newborn screening in identifying infants at risk of diseases and aiding in timely diagnosis and management, various countries have made newborn screening tests compulsory. For instance, the U.S. government has made the newborn screening test compulsory soon after birth. Since the 1960s, NBS programs have become the most effective health programs in the U.S., which test for 31 out of 35 core conditions recommended by the Uniform Screening Panel (RUSP). It is estimated that around 4 million babies are screened annually for serious disorders present at birth in the U.S.
Collaborations are also being done between public and private organizations for newborn screening. For instance, in 2021, PerkinElmer, Inc. (U.S.) collaborated with the International Society for Neonatal Screening (ISNS) to bring attention to India’s rare diseases policy in 2021 and discuss strategies to improve newborn and maternal health. The Government of India and PerkinElmer (U.S.) had also collaborated for genetic testing and newborn screening training. Additionally, in 2018, the government of Ghana collaborated with the Sickle Cell Foundation of Ghana and the U.S. Centers for Disease Control and Prevention (CDC) to provide technical assistance regarding post and pre-term screening activities, including genetic counseling, to health workers and parents. Thus, the growing importance of newborn screening testing and key developments in the newborn screening market are collectively driving the market.
Click here to: Get Free Sample Pages of this Report
Based on Product, the Consumables Segment is Expected to Account for the Largest Share of the Market in 2023
Based on product, the newborn screening market is segmented into consumables and instruments. In 2023, the consumables segment is expected to account for the largest share of the market. The main factors contributing to the large market share of this segment are the rising newborn population, repeat purchases of consumables for newborn screening tests, availability of advanced kits, and high awareness about newborn screening in developed countries. Companies and laboratories aim to provide consumables to hospitals and organizations to ensure that newborn screening is being done in almost every part of the world, including underdeveloped and developing countries. For instance, in June 2022, Novartis AG (Switzerland) announced a partnership with the American Society of Hematology (ASH) (U.S.) to provide standard-of-care practices, tools, and technologies in African nations such as Ghana, Kenya, Liberia, Nigeria, Uganda, Tanzania, and Zambia.
Based on Technology, the Tandem Mass Spectrometry Segment is Expected to Account for the Largest Share of the Market in 2023
Based on technology, the newborn screening market is segmented into immune assays & enzymatic assays, tandem mass spectrometry, molecular assays, hearing screening technologies, pulse oximetry, and other technologies. In 2023, the tandem mass spectrometry segment is expected to account for the largest share of the market. The large market share of this segment is attributed to the increasing prevalence of genetic diseases, increasing demand for specialists, and increasing awareness of newborn screening.
Based on Application, the Inherited Disorders Segment is Expected to Account for the Largest Share of the Market in 2023
Based on application, the newborn screening market is segmented into congenital heart disease, inherited disorders, infectious diseases, hearing disorders, and other applications. In 2023, the inherited disorders segment is expected to account for the largest share of 38% of the market. The large market share of this segment is due to the high prevalence of inherited disorders among newborns, variations or mutations in the genes, inherited gene defects, abnormality in genetic composition, and the growing awareness regarding newborn screening tests. For instance, in the state of Virginia, U.S., newborn screening is offered for 35 genetic or inherited disorders under the Newborn Bloodspot Screening Program. This program includes screening, follow-ups, referrals, diagnosis, and medical and dietary management.
Based on End User, the Hospitals Segment is Expected to Account for the Largest Share of the Market in 2023
Based on end user, the newborn screening market is segmented into hospitals and reference laboratories. In 2023, the hospitals segment is expected to account for the largest share of the market. The high preference of hospitals for childbirth delivery, better infrastructure, utilization of advanced techniques in the hospitals, and the availability of skilled professionals are some factors contributing to the large market share of this segment.
Asia-Pacific: Fastest Growing Regional Market
Asia-Pacific is slated to register the highest CAGR of 8.6% of in the newborn screening market during the forecast period. The high market growth in Asia-Pacific is attributed to high fertility rates in the region, improving healthcare infrastructure, and increasing disposable income. In 2020, the fertility rates in India and China were 2.2 and 1.8, respectively. Additionally, government initiatives and growing awareness in the region about newborn screening and its advantages, and rising healthcare expenditure are likely to boost the newborn screening market in Asia-Pacific.
Key Players
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years. The key players profiled in the global newborn screening market are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland). The global newborn screening market is fragmented in nature and dominated by four top players, namely, Thermo Fisher Scientific Inc. (U.S.), PerkinElmer, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Medtronic plc (France). In 2022, these players collectively accounted for a share of 60%-65% of the newborn screening market. The major companies in the newborn screening market have implemented various strategies over the years to expand their product offerings and global footprint and augment their market shares. The key strategies followed by most companies in the newborn screening market were product launches, approvals, partnerships, expansions, and acquisitions.
Scope of the Report:
Newborn Screening Market Assessment, by Product
Newborn Screening Market Assessment, by Technology
Newborn Screening Market Assessment, by Application
Newborn Screening Market Assessment, by End User
Newborn Screening Market, by Geography
Key questions answered in the report:
This study offers a detailed assessment of the newborn screening market, including the market size & forecast for various segmentations like product, application, technology, and end user. The newborn screening market studied in this report also involves the value analysis of various segments of newborn screening at regional and country levels.
The global newborn screening market is projected to reach $2.49 billion by 2030, at a CAGR of 7.9% during the forecast period.
Based on product, the newborn screening market is segmented into consumables and instruments. In 2023, the consumables segment is expected to account for the largest share of the market.
Based on application, the inherited disorders segment is expected to account for the largest share of the market in 2023.
Factors such as the rising prevalence of congenital heart diseases and genetic disorders, increasing neonatal population, and rising awareness regarding newborn screening are driving the newborn screening market. Additionally, government programs & legislation promoting newborn screening and emerging economies are likely to boost the market over the forecast period.
The key players operating in the global newborn screening market are Thermo Fisher Scientific, Inc. (U.S.), ARCHIMED Group (France), PerkinElmer, Inc. (U.S.), Medtronic plc (Ireland), Trivitron Healthcare Pvt Ltd. (India), Bio-Rad Laboratories, Inc. (U.S.), Demant A/S (Denmark), Baebies, Inc. (U.S.), ZenTech s.a. (Belgium), and F. Hoffmann-La Roche AG (Switzerland).
Growing adoption of newborn screening in emerging economies such as China, Brazil, and India, and factors such as high fertility rates in developing countries, rising healthcare expenditure, and increasing focus of governments of different countries to adopt newborn screening are the major factors expected to provide growth opportunities for players operating in this market.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection and Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Impact Analysis of Market Dynamics
4.2.2. Factor Analysis
4.3. Regulatory Analysis
4.3.1. Overview
4.3.2. U.S.
4.3.3. Canada
4.3.4. Europe
4.3.5. Asia-Pacific
4.3.5.1. China
4.3.5.2. Japan
4.3.5.3. India
4.3.6. Latin America
4.3.7. Middle East
4.4. Pricing Analysis
4.5. Industry & Technology Trends
4.5.1. Shift from Traditional Newborn Screening to Advanced Technologies
4.5.2. Laws and Initiatives Supporting Newborn Screening Across Countries
4.6. Porter’s Five Forces Analysis
4.6.1. Bargaining Power of Buyers
4.6.2. Bargaining Power of Suppliers
4.6.3. Threat of Substitutes
4.6.4. Threat of New Entrants
4.6.5. Degree of Competition
5. Newborn Screening Market Assessment—by Product
5.1. Overview
5.2. Instruments
5.3. Consumables
6. Newborn Screening Market Assessment—by Technology
6.1. Overview
6.2. Tandem Mass Spectrometry
6.3. Immune Assays & Enzymatic Assays
6.4. Molecular Assays
6.5. Pulse Oximetry
6.6. Hearing Screening Technologies
6.7. Other Technologies
7. Newborn Screening Market Assessment—by Application
7.1. Overview
7.2. Inherited Disorders
7.2.1. Metabolic Disorders
7.2.2. Hemoglobin Disorders
7.2.3. Endocrine Disorders
7.2.4. Other Inherited Disorders
7.3. Infectious Diseases
7.4. Congenital Heart Disease
7.5. Hearing Disorders
7.6. Other Applications
8. Newborn Screening Market Assessment—by End User
8.1. Overview
8.2. Hospitals
8.3. Reference Laboratories
9. Newborn Screening Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America
9.6. Middle East & Africa
10. Competition Analysis
10.1. Overview
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
11. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. PerkinElmer, Inc.
11.2. Thermo Fisher Scientific, Inc.
11.3. Bio-Rad Laboratories, Inc.
11.4. Medtronic plc
11.5. F. Hoffmann-La Roche AG
11.6. ARCHIMED Group
11.7. Trivitron Healthcare Pvt Ltd.
11.8. Demant A/S
11.9. Baebies, Inc.
11.10. ZenTech s.a.
11.11. Other Companies
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
12. Appendix
12.1. Available Customization
12.2. Related Reports
List of Tables
Table 1 Infant Mortality Rates (Deaths Per 1,000 Live Births), By Country, 2010 VS. 2019 VS. 2021
Table 2 Number of Midwifery Personnel, By Country, 2020
Table 3 Recent Key Developments in the Newborn Screening Market
Table 4 Physicians Per 1000 People, By Country, 2020
Table 5 Central Drugs Standard Control Organisation (CDSCO) Medical Device Classification
Table 6 Newborn Screening Products: Pricing Analysis
Table 7 Global Newborn Screening Market, BY Product, 2021–2030 (USD Million)
Table 8 Major Features of a Newborn Screening Instrument
Table 9 Global Newborn Screening Instruments Market, By Country/Region, 2021–2030 (USD Million)
Table 10 Global Newborn Screening Consumables Market, By Country/Region, 2021–2030 (USD Million)
Table 11 Global Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 12 Global Newborn Screening Market for Tandem Mass Spectrometry, By Country/Region, 2021–2030 (USD Million)
Table 13 Global Newborn Screening Market for Immune Assays & Enzymatic Assays, By Country/Region, 2021–2030 (USD Million)
Table 14 Some of the Companies Offering Molecular Assays
Table 15 Global Newborn Screening Market for Molecular Assays, By Country/Region, 2021–2030 (USD Million)
Table 16 Global Newborn Screening Market for Pulse Oximetry, By Country/Region, 2021–2030 (USD Million)
Table 17 Global Newborn Screening Market for Hearing Screening Technologies, By Country/Region, 2021–2030 (USD Million)
Table 18 Global Newborn Screening Market for Other Technologies, By Country/Region, 2021–2030 (USD Million)
Table 19 Global Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 20 Global Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 21 Global Newborn Screening Market for Inherited Disorders, By Country/Region, 2021–2030 (USD Million)
Table 22 Global Newborn Screening Market for Metabolic Disorders, By Country/Region, 2021–2030 (USD Million)
Table 23 Global Newborn Screening Market for Hemoglobin Disorders, By Country/Region, 2021–2030 (USD Million)
Table 24 Global Newborn Screening Market for Endocrine Disorders, By Country/Region, 2021–2030 (USD Million)
Table 25 Global Newborn Screening Market for Other Inherited Disorders, By Country/Region, 2021–2030 (USD Million)
Table 26 Global Newborn Screening Market for Infectious Diseases, By Country/Region, 2021–2030 (USD Million)
Table 27 Global Newborn Screening Market for Congenital Heart Disease, By Country/Region, 2021–2030 (USD Million)
Table 28 Global Newborn Screening Market for Hearing Disorders, By Country/Region, 2021–2030 (USD Million)
Table 29 Global Newborn Screening Market for Other Applications, By Country/Region, 2021–2030 (USD Million)
Table 30 Global Newborn Screening Market, BY End User, 2021–2030 (USD Million)
Table 31 Global Newborn Screening Market for Hospitals, By Country/Region, 2021–2030 (USD Million)
Table 32 Global Newborn Screening Market for Reference Laboratories, By Country/Region, 2021–2030 (USD Million)
Table 33 Global Newborn Screening Market, By Country/Region, 2021–2030 (USD Million)
Table 34 North America: Newborn Screening Market, By Country, 2021–2030 (USD Million)
Table 35 North America: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 36 North America: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 37 North America: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 38 North America: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 39 North America: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 40 U.S.: Macroeconomic Indicators
Table 41 U.S.: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 42 U.S.: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 43 U.S.: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 44 U.S.: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 45 U.S.: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 46 Canada: Macroeconomic Indicators
Table 47 Canada: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 48 Canada: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 49 Canada: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 50 Canada: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 51 Canada: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 52 Europe: Newborn Screening Market, By Country/Region, 2021–2030 (USD Million)
Table 53 Europe: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 54 Europe: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 55 Europe: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 56 Europe: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 57 Europe: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 58 Germany: Macroeconomic Indicators
Table 59 Germany: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 60 Germany: Newborn Screening, By Technology, 2021–2030 (USD Million)
Table 61 Germany: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 62 Germany: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 63 Germany: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 64 France: Macroeconomic Indicators
Table 65 France: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 66 France: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 67 France: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 68 France: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 69 France: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 70 U.K.: Macroeconomic Indicators
Table 71 U.K.: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 72 U.K.: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 73 U.K.: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 74 U.K.: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 75 U.K.: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 76 Italy: Macroeconomic Indicators
Table 77 Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 78 Italy: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 79 Italy: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 80 Italy: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 81 Italy: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 82 Spain: Macroeconomic Indicators
Table 83 Spain: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 84 Spain: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 85 Spain: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 86 Spain: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 87 Spain: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 88 RoE: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 89 RoE: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 90 RoE: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 91 RoE: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 92 RoE: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 93 Asia-Pacific: Newborn Screening Market, By Country/Region, 2021–2030 (USD Million)
Table 94 Asia-Pacific: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 95 Asia-Pacific: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 96 Asia-Pacific: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 97 Asia-Pacific: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 98 Asia-Pacific: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 99 China: Macroeconomic Indicators
Table 100 China: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 101 China: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 102 China: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 103 China: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 104 China: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 105 Japan: Macroeconomic Indicators
Table 106 Japan: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 107 Japan: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 108 Japan: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 109 Japan: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 110 Japan: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 111 India: Macroeconomic Indicators
Table 112 India: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 113 India: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 114 India: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 115 India: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 116 India: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 117 RoAPAC: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 118 RoAPAC: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 119 RoAPAC: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 120 RoAPAC: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 121 RoAPAC: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 122 Latin America: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 123 Latin America: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 124 Latin America: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 125 Latin America: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 126 Latin America: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 127 Brazil: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 128 Brazil: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 129 Brazil: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 130 Brazil: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 131 Brazil: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 132 Mexico: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 133 Mexico: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 134 Mexico: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 135 Mexico: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 136 Mexico: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 137 Rest of Latin America: Newborn Screening Market, By Product, 2021–2030 (USD Million)
Table 138 Rest of Latin America: Newborn Screening Market, for Technology, 2021–2030 (USD Million)
Table 139 Rest of Latin America: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 140 Rest of Latin America: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 141 Rest of Latin America: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 142 Middle East & Africa: Newborn Screening Market, By Product, 2021–2030
Table 143 Middle East & Africa: Newborn Screening Market, By Technology, 2021–2030 (USD Million)
Table 144 Middle East & Africa: Newborn Screening Market, By Application, 2021–2030 (USD Million)
Table 145 Middle East & Africa: Newborn Screening Market for Inherited Disorders, By Application, 2021–2030 (USD Million)
Table 146 Middle East & Africa: Newborn Screening Market, By End User, 2021–2030 (USD Million)
Table 147 Recent Developments, By Company, 2020–2023
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Newborn Screening Market, By Product, 2023 Vs. 2030 (USD Million)
Figure 8 Global Newborn Screening Market, By Technology, 2023 Vs. 2030 (USD Million)
Figure 9 Global Newborn Screening Market, By Application, 2023 Vs. 2030 (USD Million)
Figure 10 Global Newborn Screening Market, By End User, 2023 Vs. 2030 (USD Million)
Figure 11 Newborn Screening Market, By Geography
Figure 12 Global Newborn Screening Market: Impact Analysis of Market Drivers, Restraints, Opportunities, and Challenges (2023–2030)
Figure 13 Benefits of Newborn Screening
Figure 14 USFDA Regulatory Pathways for Medical Devices
Figure 15 EU Regulatory Pathway - IVDR 2017/746
Figure 16 China: Medical Device Classification and Premarket Requirements for IVD Devices
Figure 17 Porter's Five Forces Analysis
Figure 18 Global Newborn Screening Market, By Product, 2023 Vs. 2030 (USD Million)
Figure 19 Global Newborn Screening Market, By Technology, 2023 Vs 2030 (USD Million)
Figure 20 Protocol for Newborn Screening
Figure 21 Global Newborn Screening Market, By Application, 2023 Vs. 2030 (USD Million)
Figure 22 Two-Stage Screening Protocol for Hearing Disorders
Figure 23 Global Newborn Screening Market, By End User, 2023 Vs. 2030 (USD Million)
Figure 24 Global Newborn Screening Market, By Geography, 2023–2030 (USD Million)
Figure 25 North America: Newborn Screening Market Snapshot
Figure 26 Europe: Newborn Screening Market Snapshot
Figure 27 Asia-Pacific: Newborn Screening Market Snapshot
Figure 28 Latin America: Newborn Screening Market Snapshot
Figure 29 Key Growth Strategies Adopted By Leading Players 2020-2023
Figure 30 Newborn Screening Market: Competitive Benchmarking By Product Type
Figure 31 Newborn Screening Market: Competitive Benchmarking, By Region
Figure 32 Competitive Dashboard: Newborn Screening Market
Figure 33 PerkinElmer, Inc.: Financial Overview (2022)
Figure 34 Thermo Fisher Scientific, Inc.: Financial Overview (2022)
Figure 35 Bio-Rad Laboratories, Inc.: Financial Overview (2022)
Figure 36 Medtronic Plc: Financial Overview (2022)
Figure 37 F. Hoffmann-La Roche AG: Financial Overview (2022)
Figure 38 Demant A/S: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Mar-2024
Published Date: Apr-2023
Published Date: Apr-2017
Published Date: Mar-2016
